Clinical trial · Interventional
Effect of Aerobic Exercise on Polycystic Ovary Syndrome
Effect of Aerobic Exercise on Inflammatory Markers in Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The development of Polycystic Ovary Syndrome has been linked to chronic low-grade inflammation (PCOS). In this context, the current study looked into the effects of aerobic exercise on IL6, TNF, and C-reactive protein (CRP) in PCOS women. This was a randomized clinical trial including 40 females diagnosed with PCOS who were between the ages of 25 and 35. The participants were divided into two groups, each with an equal number of individuals: aerobic exercise (AEM) and Metformin (M). At baseline and after 12 weeks of intervention, participants' levels of IL6, TNF, and CRP were measured.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aerobic exercise in addition to Metformin treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Aerobic exercise group (AEM)
- description
- The AEM group performed aerobic exercise three times a week for 12 weeks in addition to Metformin treatment.
- interventionNames
- Other: Aerobic exercise in addition to Metformin treatment
- type
- ACTIVE_COMPARATOR
- label
- Metformin group (M)
- description
- The M group received Metformin only
- interventionNames
- Other: Aerobic exercise in addition to Metformin treatment
Primary outcomes (3)
- measure
- Level of Interleukin 6
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Mean age of 26.7 ± 2.3, body mass index (BMI) 23.6±3.5 kg/m2) . * confirmation by medical history of hyperandrogenic oligo amenorrhea (\<8 menses per year) * PCO on ultrasonography of more than 10 ovarian follicles 2-9 mm in diameter Exclusion Criteria: * Disorders known to cause hyperandrogenisms, such as congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia. * Renal or hepatic dysfunction
References
Publications (0)
Data not yet available